Pancreatic Cancer Breakthrough Nears Unique Clinical Trial
Researchers at the University of Miami have identified that blocking the IL1RAP receptor can disrupt the inflammatory network that allows pancreatic cancer to resist treatment. This discovery is moving toward a clinical trial that combines targeted therapy with chemoimmunotherapy for operable cancer patients.
Why it matters
Pancreatic cancer is notoriously difficult to treat, and this research offers a potential new pathway to improve survival rates by overcoming tumor resistance.
MIAMI (June 22, 2026) - Blocking IL1RAP, a receptor that sits at a key control point in inflammatory signaling, can disrupt the tumor-driven inflammatory network that helps pancreatic cancer resist treatment, according to new research. Led by researchers at Sylvester Comprehensive Cancer Center , part of the University of Miami Miller School of Medicine, the findings are now advancing toward a first-of-its-kind neoadjuvant clinical trial combining IL1RAP-targeted therapy with chemoimmunotherapy in patients with operable pancreatic cancer before surgery.
The article is a straightforward report on medical research findings.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in